The US Food and Drug Administration (FDA) has approved the inhaled human insulin product Afrezza (MannKind Corp) to improve glycemic control in adults with type 1 and type 2 diabetes.
Afrezza is a rapid-acting inhaled insulin to be administered prior to meals or within 20 minutes of starting a meal. It is not a substitute for long-acting insulin, and must be used in combination with long-acting insulin in patients with type 1 diabetes. It is not recommended for the treatment of diabetic ketoacidosis or in patients who smoke or who have chronic lung disease. Afrezza will have a Boxed Warning advising that acute bronchospasm has been observed in patients with asthma and chronic obstructive pulmonary disease.
4 post marketing studies are still required. Read more at http://www.medscape.com/viewarticle/827539?src=wnl_edit_newsal
